Objective To investigate the clinical efficacy and safety of fruquintinib in the treatment of metastatic colorectal cancer(mCRC).Methods The clinical data of 48 mCRC patients receiving fruquintinib as third-or later-treatment in our hospital from January 2019 to De-cember 2021 were collected.The treatment,progression-free survival(DFS)and incidence of adverse reactions were analyzed.Results The 48 mCRC patients received 2 to 17 cycles of fruquintinib treatment.Complete response(CR)was not observed(0.0％),partial response(PR)was observed in three cases(6.2％),stable disease(SD)in 32 cases(66.7％),and progressive disease(PD)in 13 cases(27.1％).The disease control rate(DCR)was 72.9％,and the objective response rate(ORR)was 6.2％.The median PFS was 4.9 months.The median PFS of patients with fruquintinib monotherapy and of those with fruquintinib combination therapy was 4.7 months and 6.2 months,respectively(P=0.445).Common adverse reactions in the 48 patients included hypertension,hand-foot-skin reactions,abnormal thyroid function,proteinuria,fatigue,and liver function abnormalities.31.3％(15/48)of patients experienced grade 3-4 adverse reactions,mainly presented as hypertension and hand-foot-skin reactions.Conclusions Fruquintinib demonstrates clear clinical benefits and good tolerability as third-or later-line treat-ment of mCRC.Overall adverse reactions are manageable,and further exploration of its combination with immunotherapy is warranted.
维普
万方数据
